Breaking News
Sort by:
Top Post
NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business
NEC Corporation and NOI announced that NOI will be realigned as a subsidiary of NEC […]
Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa
Nanoscope Therapeutics, today announced topline results from the Phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE […]
Transcenta's Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer
Transcenta, a clinical-stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of […]
FDA Issues Draft Guidance Aimed at Improving Oncology Clinical Trials for Accelerated Approval
The United States Food and Drug Administration (FDA) issued draft guidance, Clinical Trial Considerations to […]
Genprex CEO Commends FDA's Initiative to Accelerate Approval Process for Gene Therapies
Rodney Varner, CEO of Genprex, a clinical-stage gene therapy company focused on developing life-changing therapies […]
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome
Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure […]
Medtronic to Boost AI Innovation with New Platform Introduction
Medtronic, a global leader in healthcare technology, has announced Cosmo Pharmaceuticals and NVIDIA plan to […]
Ionis Accounces FDA Advisory Committee Voted Unanimously for a Potential Accelerated Approval of Tofersen for SOD1-ALS
Ionis has announced the outcome of the United States Food and Drug Administration’s (FDA) Peripheral […]
Kuria Therapeutics Completes FDA Pre-IND Consultation for Topical Nrf2 Activator for Corneal Endothelial Disease
Kuria Therapeutics, a pharmaceutical company developing novel ophthalmic and dermal therapeutics, is pleased to announce […]
TrueBinding Granted Type B End-of-Phase 2 Meeting with FDA for Discussion of Accelerated Development Pathway for TB006 Alzheimer's Disease Treatment
TrueBinding, a clinical-stage biotherapeutic company creating new and exciting molecules for applications in neurodegenerative and […]
Mirum Announces Label Expansion for LIVMARLI in the United States to Include Infants Three Months of Age and Older
Mirum Pharmaceuticals today announced that the United States Food and Drug Administration (FDA) has approved […]
- Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis Read more
- NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business Read more
- Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Read more
- Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Read more
- Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Read more